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Overall survival after treatment for metastatic uveal 
melanoma: a systematic review and meta-analysis
Elina S. Rantalaa,c, Micaela Hernbergb and Tero T. Kiveläa   
The overall survival (OS) of patients with metastatic 
uveal melanoma is short, the evidence for effectiveness 
of treatments is limited, and no consensus on the choice 
of treatment exists. We aimed to advance interpretation 
of OS as an outcome by pooling peer-reviewed data. 
The design is a systematic review and meta-analysis. We 
searched PubMed from 1 January 1980, to 29 March 2017, 
for articles reporting patient-level survival in Kaplan–
Meier or numerical form. We digitized survival graphs, 
pooled individual survival times, calculated median OS 
by treatment modality, and compared each modality by 
the log-rank test and Cox regression using conventional 
chemotherapy (CHT) as a reference. Individual-level 
data were obtained from 78 articles with 2494 patients. 
The median OS across all treatment modalities was 1.07 
years (range: 0.59–2.50 years). Pooled OS reported after 
isolated hepatic perfusion [median OS: 1.34 years; hazard 
ratio (HR): 0.92, 95% confidence interval (CI): 0.87–0.97, 
P = 0.0040], immunoembolization (median OS: 1.63; HR: 
0.97, 95% CI: 0.95–1.00, P = 0.0080), and surgery (median 
OS: 1.43; HR: 0.94, 95% CI: 0.92–0.96, P < 0.0001) was 
longer, and after checkpoint inhibitor shorter (median OS: 
0.59; HR: 1.13, 95% CI: 1.06–1.20, P < 0.0001) than after 
CHT (median OS: 0.91 years), but subject to identifiable 
confounding factors. OS following other modalities did not 
differ from CHT. Reported OS was unassociated with the 
decade of publication, but depended on the percentage of 
first-line treated patients. Our results suggest no clinically 
significant difference in OS by treatment modality or 
decade. Most of the difference in reported OS likely is 
attributable to surveillance, selection, and publication bias 
rather than treatment-related prolongation. Our pooled 
data provide benchmarks for future trials. Melanoma Res 
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Introduction
Uveal melanoma is the most common primary malignant 
intraocular tumour in adults [1]. The incidence varies by 
age, ethnicity and latitude from 0.1 to 8.6 per million [2,3]. 
More than half result in metastases [4] and thereafter the 
median overall survival (OS) historically is less than 6 
months [5]. The liver remains the only site of metastasis 
in half of the patients [5,6]. Improvements in managing 
the primary tumour have not translated into decreased 
metastasis rate or longer survival [1,7].
Over the last decade, considerable development has 
occurred in targeted therapy for metastatic cutaneous 
melanoma [8], but new treatments have not shown equal 
survival benefits in metastatic uveal melanoma [9,10] 
and no standard first-line treatment exists. Because of 
the small number of patients, few randomized trials have 
been conducted [11–14]. We aimed to advance the inter-
pretation of survival outcomes by extracting individu-
al-level OS data from peer-reviewed articles by digitizing 
Kaplan–Meier curves and by pooling data for comparison.
Patients and methods
Search strategy and selection criteria
We specified the methods and inclusion criteria of our 
systematic review and meta-analysis according to the 
PRISMA 2009 guidelines [15] and performed a literature 
search without language restrictions to identify all articles 
on metastatic uveal melanoma in peer-reviewed journals 
from 1 January 1980, through 29 March 2017.
We searched PubMed with the terms uveal melanoma, 
choroidal melanoma, ciliary body melanoma, ciliocho-
roidal melanoma, iridociliary melanoma, iris melanoma, 
intraocular melanoma and ocular melanoma, combined 
with metast* or stage IV and treatment (PubMed search 
strategy, Supplemental digital content 1, http://links.lww.
com/MR/A107). One author (E.S.R.) reviewed the titles 
and abstracts to confirm the subject was treatment of 
metastatic uveal melanoma. Articles on animal models, 
laboratory investigations, imaging, primary or locally 
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recurrent tumour, prognosis, staging, quality-of-life, 
reviews and case reports were excluded. Studies with less 
than three patients were excluded to limit most obvious 
publication bias.
Two authors (E.S.R. and T.T.K.) reviewed the full text 
of relevant articles. Studies that included primary cuta-
neous or mucosal melanoma were excluded unless 
patients with uveal melanoma were reported separately. 
If the primary was designated ocular, we e-mailed the 
first author to exclude conjunctival melanomas. Of 17 
authors, 14 responded and we categorized the publica-
tions accordingly; the remaining articles were excluded. 
If it was uncertain whether patients in any two articles 
overlapped, we excluded the article with fewer patients. 
Finally, we checked the reference lists against our search 
and archives to identify additional ones.
Data analysis
Our endpoint was OS. If the article referred to RECIST 
criteria [16], we assumed OS to begin from initiating 
study treatment until censoring or death. If multiple defi-
nitions were provided, we chose the one corresponding to 
the Kaplan–Meier graph. We tabulated the author, publi-
cation year, treatment, study design, number of patients, 
first-line treatments and previous surgeries, OS with defi-
nition, and geographical origin of each publication (see 
Supplementary Table, Supplemental digital content 2, 
http://links.lww.com/MR/A108, which summarizes the char-
acteristics of included studies on treatment for metastatic 
uveal melanoma). If the median OS was unreported, we 
tabulated it from our digitized Kaplan–Meier curve; in 
case the reported OS differed from our digitized one, we 
suggest an explanation.
We extracted the individual-level survival times directly 
when reported in the text or a table. In general, patient-
level data were not tabulated and we scanned the 
Kaplan–Meier curve(s) to TechDig (version 2.0.0.1; 
shareware by Ronald B. Jones, Mundelein, Illinois, USA) 
to manually obtain the survival time corresponding to 
each step for deaths and tick for censored events. If the 
latter were not displayed, but the at-risk table was pro-
vided, the at-risk reduction minus deaths was taken to 
be the number of censored events during each interval, 
which we assigned to its midpoint [17]. If the at-risk table 
was absent, we calculated the total number of censored 
events from the total number of patients and deaths. 
We then transferred the digitized survival times to Stata 
(version 13; Stata Corp., College Station, Texas, USA), 
plotted the survival curve and overlaid it as a transpar-
ent layer over the appropriately resized published graph 
in Paint Shop Pro X6 (Corel Corp., Ottawa, Canada). 
We visually identified intervals with censored event(s), 
assigned these events by trial-and-error and repeated this 
process until the survival graphs matched. We verified 
other digitized Kaplan–Meier graphs similarly. The data 
are available from the Zenodo Digital Repository (https://
doi.org/10.5281/zenodo.1490563).
We prospectively identified the main treatment modal-
ities: conventional chemotherapy (CHT), chemoimmu-
notherapy (CIT), hepatic intra-arterial chemotherapy 
(HIA), transarterial chemoembolization (TACE), isolated 
hepatic perfusion (IHP), checkpoint inhibitor (CPI), 
protein kinase inhibitor, selective internal radiation ther-
apy, immunoembolization (IE) and immunosuppressant. 
Moreover, we found data on liver-directed thermotherapy 
(laser-induced thermotherapy and stereotactic radiofre-
quency ablation), vaccine and surgery. Best supportive 
care was excluded [18–21].
We compared individual studies on each treatment 
modality to assess heterogeneity, and then compared 
studies within each modality according to the agents 
used, if applicable. We next compared each treatment 
modality, in aggregate, against CHT and, finally, limited 
our analysis to first-line treatments whenever possible. 
We tabulated the median OS with the 95% confidence 
interval (CI), plotted comparative Kaplan–Meier graphs 
and used the log-rank test and univariable Cox propor-
tional hazards regression analysis to compare modalities, 
setting significance at 0.05.
Results
Our search identified 1663 records on metastatic uveal 
melanoma. Review of abstracts found 197 articles on 
the treatment of at least three patients (Fig.  1; see 
Supplementary Table for exact patient number for each 
article, Supplemental digital content 2, http://links.lww.
com/MR/A108, which summarizes the characteristics of 
included studies on treatment for metastatic uveal mel-
anoma). From the reference lists and our archives, we 
found five additional articles. We excluded six articles 
because of uncertainty in terms of whether they shared 
patients with other publications (Supplementary Text, 
Supplemental digital content 3, http://links.lww.com/MR/
A109, which summarizes the excluded studies). Seventy-
eight of the 196 articles contained data digitizable for a 
pooled Kaplan–Meier graph.
Of the 78 articles, 37 (47%) were prospective and 41 
(53%) were retrospective (see Supplementary Table, 
Supplemental digital content 2, http://links.lww.com/MR/
A108, which summarizes the characteristics of included 
studies on treatment for metastatic uveal melanoma). OS 
was reported from the diagnosis of metastases in eight 
(10%), enrolment in six (8%), initiation of study treat-
ment in 59 (76%) and was undefined in five (6%) publi-
cations. Multiple definitions were adopted in 11 articles. 
Nineteen (24%) studies were funded totally or partially 
by industry, the authors reported a conflict of interest 
with the industry, or both. In 36 (46%) studies, the indus-
try was not involved, and in 23 (29%), this information 
was unavailable.
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Altogether, we included 2494 patients, ranging from three 
to 171 by study (Supplementary Table, Supplemental 
digital content 2, http://links.lww.com/MR/A108); 478 were 
censored observations. Of the latter, 182 (38%), 305 
(64%) and 379 (79%) had occurred by 1, 2 and 3 years, 
respectively. The median OS was 1.07 years (95% CI: 
1.00–1.13), but the survival rate decreased rapidly from 
52% (95% CI: 50–54) at 1 year to 25% (95% CI: 23–26) 
at 2 years, and 13% (95% CI: 12–15) at 3 years (Table 1). 
The median OS on the basis of publications that reported 
first-line treatments was 1.03 years (95% CI: 0.95–1.14) 
for 510 patients, and the survival rate was 51% (95% CI: 
47–55), 21% (95% CI: 18–25) and 10% (95% CI: 7–13) 
at 1, 2 and 3 years, respectively (see Table 1 for data by 
therapeutic modality).
We provide Kaplan–Meier graphs by article for each treat-
ment modality (Supplementary Fig. S1, Supplemental 
digital content 4, http://links.lww.com/MR/A110) and CHT 
agent (Supplementary Fig. S2, Supplemental digital con-
tent 4, http://links.lww.com/MR/A110) to show heterogene-
ity between articles, and graphs for each modality against 
CHT for all patients (50 patients or more, Fig. 2; fewer 
than 50 patients; Supplementary Fig. S3, Supplemental 
digital content 4, http://links.lww.com/MR/A110) and for 
first-line treatments, as available (Fig.  3). OS was com-
parable to that with CHT for CIT, HIA, TACE, protein 
kinase inhibitor and selective internal radiation therapy 
(P = 0.13–0.80). We also show components of survival for 
studies that report interval from diagnosis of metastases 
to the initiation of study treatment; this interval varied 
widely and adds to heterogeneity (Supplementary Fig. 
S4, Supplemental digital content 4, http://links.lww.com/
MR/A110). IHP [hazard ratio (HR): 0.92, P = 0.0040] and 
IE (HR: 0.97, P = 0.0080) were associated with longer 
OS, and CPI (HR: 1.13, P < 0.0001) with shorter OS than 
CHT (Table 2 and Fig. 2). Patient-level data on first-line 
treatments were unavailable for these treatment modal-
ities. However, sensitivity analysis showed that the dif-
ference in OS after IHP depends solely on the largest 
of the six studies in which OS was exceptionally long 
(Supplementary Fig. S5, Supplemental digital content 
4, http://links.lww.com/MR/A110) [22], whereas only about 
8% of CPI treatments in the nine studies aggregated 
were first-line (Supplementary Table, Supplemental dig-
ital content 2, http://links.lww.com/MR/A108). The IE data 
derived from a single-centre phase I and a subsequent 
phase II trial [12,23].
To determine whether the treatment outcome has 
improved over time, we compared the median OS accord-
ing to publishing decade. The number of patients was 
1994 after exclusion of surgery. From the 1980s to the 
2010s, OS was 0.92 (95% CI: 0.66–1.50; 2% of patients), 
1.16 (0.93–1.51; 2%), 1.03 (0.96–1.12; 26%) and 0.91 (0.85–
0.99; 70%) years, showing no improvement (log-rank test 
for trend P = 0.66; Supplementary Fig. S6, Supplemental 
digital content 4, http://links.lww.com/MR/A110).
1663 records identified
1661 unique records
2 duplicates removed
197 full-text articles
assessed for eligibility
1464 excluded on the basis of
the title or abstract: 
419 primary tumor treatment,
characteristics
232 other disease/condition
373 imaging, histological
analysis, laboratory
testing
185 case reports
106 review, no original data
81 prognosis, staging, quality
of life analyses
62 animal models
6 only locally recurrent
79 articles included in the
analysis 
118  full-text articles excluded
        on the basis of full-text:
39 individual survival not
reported 
19 incomplete survival data
14 no treatment of metastasis
reported or not speci ed
13 no original data 
11 cutaneous vs uveal melanoma
not speci ed
10 less than 3 patients
7 “ocular melanoma” i.e. no
information whether uveal or
not
4 cutaneous melanoma 
1 no metastasis i.e. adjuvant
therapy
78 articles included in the
meta-analysis
6 articles removed because
of duplicate patients
5 additional articles identified
through manual search
Fig. 1
Study flow chart.
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To estimate bias from treatment line, we categorized 
articles according to the percentage of patients who 
received first-line treatment. Studies with exclusively 
first-line treatments had the longest and those with no 
first-line treatments had the shortest pooled OS; survival 
times associated with increasing percentages of first-line 
treated patients were intermediate, but not ordered log-
ically (log-rank test for trend P < 0.0001; Supplementary 
Fig. S7, Supplemental digital content 4, http://links.lww.
com/MR/A110; Table  2). When the number of first-line 
treatments was unreported, OS was longest, a finding not 
explained either by more frequent reporting of OS from 
diagnosis versus enrolment or study treatment (6 vs. 26% 
for all first-line treatments group) or by more frequent 
liver-targeted therapies (67 vs. 67%, respectively).
Discussion
In our meta-analysis, the median OS after metastatic 
uveal melanoma was 1.07 years for 2494 patients, ranging 
from 0.84 to 1.34 years for main treatment modalities 
other than CPI (0.59) and IE (1.63). These differences 
likely would diminish if the analysis could be limited 
to first-line treatments [24], but such patient-level data 
were available only for CHT, CIT, HIA and TACE. The 
median OS was longer (1.43) than average for surgically 
treated patients, but only selected ones are eligible 
because of frequent widespread hepatic metastases, even 
when surveilled intensively [19].
Traditionally, phase II trials have reported the objective 
response rate as the endpoint. A review of 841 patients 
from 40 articles of metastatic uveal melanoma analysed 
the objective response rate, but not OS [9]; of the 78 
articles in our meta-analysis, 70% were not available for 
that study. OS arguably is a more meaningful outcome 
because, for the patient, disease stabilization or even 
slower progression matters [25]. We chose OS as the end-
point also because it was most frequently available at 
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Fig. 2
Kaplan–Meier plots (a–h) of overall survival after metastatic uveal melanoma, pooled data for each treatment modality administered to more than 
50 patients, compared against conventional chemotherapy. P values were calculated using the log-rank test. CHT, conventional chemotherapy; 
CIT, chemoimmunotherapy; CPI, checkpoint inhibitor; HIA, hepatic intra-arterial chemotherapy; IE, immunoembolization; IHP, isolated hepatic 
perfusion; IS, immunosuppressant; LDT, liver-directed thermotherapy; PKI, protein kinase inhibitor; SIRT, selective internal radiation therapy; TACE, 
transarterial chemoembolization.
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Fig. 3
Kaplan–Meier plots (a–c) of overall survival after metastatic uveal melanoma, pooled data for each treatment modality, restricted to first-line 
treatments, compared against conventional chemotherapy. P values were calculated using the log-rank test. CHT, conventional chemotherapy; CIT, 
chemoimmunotherapy; HIA, hepatic intra-arterial chemotherapy; TACE, transarterial chemoembolization.
Table 2  Heterogeneity between publications reporting treatment for metastatic uveal melanoma and comparison of pooled overall 
survival data by treatment modalities against conventional chemotherapy
    All patients First-line treated patients
Treatments
Studies  
(n)
Heterogeneity 
between the articles 
estimated by  
log-rank test 
P value
Observed 
deaths/all 
patients  
[n (%)]
Conventional 
chemotherapy 
compared with 
treatment modality
Log-rank 
test
 P value
Cox regression  
HR (95% CI) P value
Log-rank 
test  
(P value)
Cox regression  
HR (95% CI) P value
CHT 10 0.020 222/272 (82) – – – – – – –
CIT 6 0.13 101/107 (94) CIT vs. CHT 0.80 0.97 (0.76–1.23) 0.80 0.64 1.10 (0.73–1.66) 0.65
HIA 10 0.0005 306/355 (86) HIA vs. CHT 0.17 0.98 (0.96–1.01) 0.17 0.29 0.98 (0.95–1.02) 0.29
TACE 15 <0.0001 401/484 (83) TACE vs. CHT 0.38 1.01 (0.99–1.03) 0.38 0.81 1.00 (0.97–1.04) 0.81
IHP 6 0.057 123/147 (84) IHP vs. CHT 0.0037 0.92 (0.87–0.97) 0.0040 – – –
CPI 9 0.22 227/318 (71) CPI vs. CHT 0.0002 1.13 (1.06–1.20) <0.0001 – – –
PKI 7 0.037 108/132 (82) PKI vs. CHT 0.13 1.04 (0.99–1.09) 0.13 – – –
SIRT 3 0.0008 59/71 (83) SIRT vs. CHT 0.38 1.02 (0.97–1.07) 0.38 – – –
IE 2 0.34 52/56 (93) IE vs. CHT 0.0073 0.97 (0.95–1.00) 0.0080 – – –
IS 1 – 12/14 (86) IS vs. CHT 0.30 1.02 (0.98–1.07) 0.31 – – –
LDT 2 0.57 16/24 (67) LDT vs. CHT 0.0006 0.94 (0.91–0.98) 0.0010 – – –
Vaccine 1 – 12/14 (86) Vaccine vs.  
CHT
0.088 0.95 (0.91–1.01) 0.092 – – –
Surgery 9 <0.0001 377/571 (66) Surgery vs.  
CHT
<0.0001 0.94 (0.92–0.96) <0.0001 – – –
CHT, conventional chemotherapy; CI, confidence interval; CIT, chemoimmunotherapy with interferon and interleukin; CPI, checkpoint inhibitor; HIA, hepatic intra-arterial 
chemotherapy; HR, hazard ratio; IE, immunoembolization; IHP, isolated hepatic perfusion; IS, immunosuppressant; LDT, liver-directed thermotherapies; PKI, protein 
kinase inhibitor; SIRT, selective internal radiation therapy; TACE, transarterial chemoembolization.
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the patient level and least subject to interpretation. The 
past 25 years in Uveal Melanoma: a Meta-Analysis Study, 
a so far unpublished meta-analysis of the International 
Rare Cancers Initiative, aims to pool original data of 
970 patients from 29 phase II trials to establish bench-
marks of 6-month progression-free survival and 1-year 
OS [26,27]. Interim subgroup analyses based on 677 and 
463 patients are available as abstracts without pooled OS 
[26,27]. Another review tabulated the median OS from 36 
articles without pooling data [10].
Most studies that we included were retrospective and had 
small sample sizes. A consequent limitation is the high 
level of heterogeneity from publication and selection bias 
and variable case mix. Some metastases were detected by 
surveillance and others after symptoms developed; some 
patients were treatment-naive and others had been pre-
treated heavily. We made the latter bias apparent by tab-
ulating the percentage of first-line treatments. Resection 
of metastases, even when partial, may prolong survival 
[19,28]. We highlighted this bias by reporting the number 
of patients who underwent a previous resection. Other 
sources of bias including performance status, metastasis 
sites and burden, and liver function were reported varia-
bly and not at the patient level, and we could not adjust 
for them. However, bias should become averaged when 
data from an increasing number of studies are pooled.
Heterogeneity was evident even in the CHT group used 
as a comparison base. All patients treated with fotemus-
tine derived from the largest prospective randomized 
study, and all treatments were first-line [11], whereas 
patients treated with treosulfan plus gemcitabine came 
from four publications and 43% of treatments were higher 
than first line [29–32]. Nevertheless, we detected no OS 
difference between these regimens (P = 0.94).
With respect to treatments other than CHT, a prospective 
multicentre study [33] analysed the efficacy of BOLD 
chemotherapy plus recombinant interferon α-2b, a form 
of CIT, because of encouraging pilot reports [34,35], but 
did not confirm its efficacy. Our pooled data from five CIT 
studies confirmed no difference compared with CHT.
Administration of chemotherapeutic agents to the hepatic 
artery with or without blocking the blood supply of the 
metastases is logical considering that the liver typically 
is the first and the only site of metastasis [5,6]. IHP with 
melphalan, sometimes with an additional agent, was asso-
ciated with a longer OS than CHT. It is offered in dedi-
cated centres, one of which [22] was responsible for the 
difference, sometimes with considerable complications, 
weighted mean mortality 6% [22].
Studies with no first-line treatments expectedly reported 
the shortest pooled median OS, reflecting the salvage 
nature of the treatment. We addressed bias from vary-
ing percentages of first-line treatments by tabulating the 
percentages and analysing articles accordingly. Although 
survival was intermediate for all combinations of first-line 
and higher-line treatments, it did not logically decrease 
with decreasing percentage of first-line treatments, indi-
cating a complicated source of bias that included variable 
time from diagnosis of metastases. Nevertheless, the rarity 
of first-line treatments explained worse survival after CPI. 
Analysis of the OS according to publishing decade found no 
improvement over time. No valid comparison of immuno-
therapy combined with other treatments was possible and 
more trials using immunotherapy backbone are needed.
Different methodologies in original publications posed 
a challenge. The method to calculate the median OS 
was unreported occasionally. Kaplan–Meier graphs often 
lacked at-risk tables and censored events. Assigning 
censored events to the midpoint of each interval, whilst 
recreating each curve, potentially introduced bias when 
we pooled data from several studies, and their cen-
sored events and deaths became intermixed. This bias 
should become less influential with increasing num-
bers of pooled studies. On the basis of the difficulties 
in extracting data, we propose guidelines for report-
ing on treatment for metastatic uveal melanoma (see 
Supplementary Text, Supplemental digital content 5, 
http://links.lww.com/MR/A111, which proposes guidelines 
for future reporting of studies on treatment for metastatic 
uveal melanoma). As previously done for cutaneous mel-
anoma [36], we provide a benchmark dataset to facilitate 
future trial design and analysis (see Supplementary Text, 
Supplemental digital content 6, http://links.lww.com/MR/
A112, which describes overall survival benchmark; and 
the Supplementary Excel file, Supplemental digital con-
tent 7, http://links.lww.com/MR/A113, which includes the 
numerical data to calculate the historical survival curve). 
We acknowledge that our meta-analysis cannot replace 
prospective randomized studies.
Conclusion
Despite suggestions in uncontrolled studies [37–39], 
patient-level data aggregated from peer-reviewed articles 
provide no compelling evidence for a longer median OS 
for patients with metastatic uveal melanoma by any treat-
ment modality, confirming traditional reviews [9,10] and 
rare previous randomized trials [11–14]. The difference 
in OS between nonrandomized studies likely is attribut-
able to surveillance, selection and publication bias rather 
than treatment-related prolongation.
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